Two-Year Data from ENDEAVOR IV, Head-to-Head Comparison of Endeavor®
and Taxus® Drug-Eluting
Stents, Features Prominently in Tuesday's Late-Breaking Clinical Trials
Session
Medtronic, Inc. (NYSE:MDT), today announced its plans for the
Transcatheter Cardiovascular Therapeutics (TCT) meeting Oct. 12–17
in Washington, D.C.
Dr. Martin B. Leon, founder and chairman emeritus of the Cardiovascular
Research Foundation in New York, will present two-year data from
ENDEAVOR IV on Tuesday, Oct. 14, at approximately 12:15 p.m. in the Main
Arena during a late-breaking clinical trials session. On staff at
Columbia University Medical Center and New York-Presbyterian Hospital,
Dr. Leon serves as principal investigator of ENDEAVOR IV, a head-to-head
comparison of Medtronic’s Endeavor and Boston
Scientific’s Taxus drug-eluting coronary
stents.
Dr. Leon’s presentation will be followed by a
presentation on ODESSA as part of the same session. Six-month results
from ODESSA, a study that used optical coherence tomography to compare
stent strut coverage in patients treated with the Endeavor, Taxus and
Johnson & Johnson’s Cypher®
drug-eluting stents, will be presented by Dr. Giulio Guagliumi of
Ospedali Riuniti di Bergamo in Italy. Stent strut coverage relates to
endothelialization.
Data on Medtronic’s broad portfolio of
cardiovascular innovations will be discussed in scores of oral
presentations and e-posters during TCT 2008, which marks the meeting’s
20th anniversary.
E-Posters Available Sunday Afternoon
With a few exceptions, poster presentations accepted for TCT will be
available electronically Sunday afternoon, Oct. 12.
